Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.

Journal: European journal of drug metabolism and pharmacokinetics
PMID: 32930952

Abstract

BACKGROUND AND OBJECTIVE: Deferasirox is an oral iron chelator used to reduce iron levels in iron-overloaded patients with transfusion-dependent anemia or non-transfusion-dependent thalassemia. This study investigated the effects of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and constructed a pharmacokinetic prediction model based on physiologic factors and genetic polymorphism data.

Authors

  • Jinliang Chen
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Yichao Xu
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Honggang Lou
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Bo Jiang
    Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, Nanjing Forestry University, Nanjing 210037, China. 111501206@njfu.edu.cn.
  • Rong Shao
    Center of Clinical Pharmacology, School of Medicine, The Second Affiliated Hospital of Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
  • Dandan Yang
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Yin Hu
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Zourong Ruan
    Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.

Keywords

External Resources

Popular Topics
Recent Journals